Roche Agrees to Buy Lonza's Singapore Manufacturing Facility

Lonza has announced that Genentech Singapore, a wholly-owned member of the Roche Group, has elected to exercise an option to purchase from Lonza its cell culture biologic manufacturing facility in Singapore for $290 million plus additional milestone payments of $70 million. The facility, which is mechanically completed, will be merged with Genentech Singapore's existing biologic manufacturing facility. As part of the integration between Roche's and Genentech's combined technical operations, the biotechnology production facilities in Singapore currently operating...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers